» Articles » PMID: 26366408

The Major Prognostic Features of Nuclear Receptor NR5A2 in Infiltrating Ductal Breast Carcinomas

Overview
Journal Int J Genomics
Publisher Wiley
Date 2015 Sep 15
PMID 26366408
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

Background. Gene expression profiles of 181 breast cancer samples were analyzed to identify prognostic features of nuclear receptors NR5A1 and NR5A2 based upon their associated transcriptional networks. Methods. A supervised network analysis approach was used to build the NR5A-mediated transcriptional regulatory network. Other bioinformatic tools and statistical methods were utilized to confirm and extend results from the network analysis methodology. Results. NR5A2 expression is a negative factor in breast cancer prognosis in both ER(-) and ER(-)/ER(+) mixed cohorts. The clinical and cohort significance of NR5A2-mediated transcriptional activities indicates that it may have a significant role in attenuating grade development and cancer related signal transduction pathways. NR5A2 signature that conditions poor prognosis was identified based upon results from 15 distinct probes. Alternatively, the expression of NR5A1 predicts favorable prognosis when concurrent NR5A2 expression is low. A favorable signature of eight transcription factors mediated by NR5A1 was also identified. Conclusions. Correlation of poor prognosis and NR5A2 activity is identified by NR5A2-mediated 15-gene signature. NR5A2 may be a potential drug target for treating a subset of breast cancer tumors across breast cancer subtypes, especially ER(-) breast tumors. The favorable prognostic feature of NR5A1 is predicted by NR5A1-mediated 8-gene signature.

Citing Articles

p53R172H and p53R245W Hotspot Mutations Drive Distinct Transcriptomes in Mouse Mammary Tumors Through a Convergent Transcriptional Mediator.

McDaniel J, Morrissey R, Dibra D, Patel L, Xiong S, Zhang Y Cancer Res Commun. 2024; 4(8):1991-2007.

PMID: 38994678 PMC: 11310746. DOI: 10.1158/2767-9764.CRC-24-0128.


High expression of transmembrane P24 trafficking protein 9 predicts poor prognosis in breast carcinoma.

Ju G, Xu C, Zeng K, Zhou T, Zang L Bioengineered. 2021; 12(1):8965-8979.

PMID: 34635011 PMC: 8806988. DOI: 10.1080/21655979.2021.1990673.


Nr5a2 promotes tumor growth and metastasis of gastric cancer AGS cells by Wnt/beta-catenin signaling.

Liu L, Li Y, Pan B, Zhang T, Wei D, Zhu Y Onco Targets Ther. 2019; 12:2891-2902.

PMID: 31114234 PMC: 6489909. DOI: 10.2147/OTT.S201228.


NR1H3 Expression is a Prognostic Factor of Overall Survival for Patients with Muscle-Invasive Bladder Cancer.

Wu J, Wan F, Sheng H, Shi G, Shen Y, Lin G J Cancer. 2017; 8(5):852-860.

PMID: 28382148 PMC: 5381174. DOI: 10.7150/jca.17845.

References
1.
Sala A . B-MYB, a transcription factor implicated in regulating cell cycle, apoptosis and cancer. Eur J Cancer. 2005; 41(16):2479-84. DOI: 10.1016/j.ejca.2005.08.004. View

2.
Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M . Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2014; 136(5):E359-86. DOI: 10.1002/ijc.29210. View

3.
Riggins R, Mazzotta M, Maniya O, Clarke R . Orphan nuclear receptors in breast cancer pathogenesis and therapeutic response. Endocr Relat Cancer. 2010; 17(3):R213-31. PMC: 3518023. DOI: 10.1677/ERC-10-0058. View

4.
Guerin M, Sheng Z, Andrieu N, Riou G . Strong association between c-myb and oestrogen-receptor expression in human breast cancer. Oncogene. 1990; 5(1):131-5. View

5.
Kim K, Moon S, Kim S, Kang K, Yoon J, Ahn S . Transcriptional regulation of MDR-1 by HOXC6 in multidrug-resistant cells. Oncogene. 2012; 32(28):3339-49. DOI: 10.1038/onc.2012.354. View